ICA1L (Islet cell autoantigen 1-like, UniProt Q8NDH6) is a human protein-coding gene on chromosome 2 (2q33) named for its similarity to ICA1 (also known as ICA69), a 69-kDa islet cell autoantigen originally identified in type 1 diabetes (www.medchemexpress.eu). The ICA1L gene was initially described as an ALS2CR14/ALS2CR15 candidate in the amyotrophic lateral sclerosis 2 critical region, but its product’s function has only recently begun to be elucidated (www.reactome.org). ICA1L encodes a cytosolic protein that contains an arfaptin homology domain, which is a member of the BAR (Bin/Amphiphysin/Rvs) domain family (www.ncbi.nlm.nih.gov). BAR domains are dimerization and lipid-binding modules known to sense and induce membrane curvature (www.ncbi.nlm.nih.gov). Like its ICA69 paralog, ICA1L is predicted to function as a membrane scaffolding/adaptor protein involved in intracellular trafficking and organelle biogenesis (www.genecards.org). Below, we detail the current understanding of ICA1L’s structure, biological role, subcellular localization, and involvement in cellular pathways, drawing on the latest research and expert analyses.
ICA1L shares significant homology with ICA1/ICA69, particularly in the N-terminal BAR/arfaptin domain (approximately amino acids 46–248) (www.ncbi.nlm.nih.gov). The BAR (arfaptin) domain of ICA1L is a curvature-sensing module that allows the protein to form dimers and bind to membrane surfaces (www.ncbi.nlm.nih.gov). This domain architecture suggests that ICA1L can detect and drive membrane curvature, similar to other BAR domain proteins that deform lipid bilayers during vesicle budding and fusion (www.ncbi.nlm.nih.gov). Notably, ICA69 itself contains an N-terminal BAR domain and a conserved C-terminal region of unknown function (www.ncbi.nlm.nih.gov). By analogy, ICA1L likely has a similar two-domain organization, with the BAR domain mediating membrane interactions and dimerization, and a C-terminal segment that may confer specificity (for example, by binding particular partner proteins or membranes). Consistent with this, the BAR-domain family to which ICA1L belongs is known for dimeric banana-shaped scaffolds that bind and tubulate membranes, contributing to vesicle formation (www.ncbi.nlm.nih.gov). In line with its domain makeup, ICA1L is predicted to enable protein domain-specific binding activity (maayanlab.cloud), indicating it may interact with other proteins via recognition of particular domains or motifs, as is common for scaffolding proteins.
Experimental evidence from the ICA1L paralog ICA69 supports these structural inferences. ICA69’s BAR domain mediates heterodimerization with the protein PICK1 (Protein Interacting with C Kinase-1) (www.ncbi.nlm.nih.gov), suggesting that ICA1L’s BAR domain could likewise engage in BAR–BAR domain interactions. Indeed, proteomic interaction studies have identified a physical interaction between ICA1L and PICK1 (www.reactome.org). PICK1 itself contains a PDZ domain and a BAR-like region and is involved in vesicle trafficking and receptor localization. The ability of ICA1L to bind PICK1 via its BAR domain implies a conserved structural coupling similar to the ICA69–PICK1 complex. In the ICA69/PICK1 case, the BAR domain heterodimers form a scaffold that can attach to membranes and regulate cargo trafficking (www.ncbi.nlm.nih.gov). Thus, ICA1L’s structural features strongly suggest it serves as a dimeric membrane-binding adapter, cooperating with partners like PICK1 to stabilize or shape vesicular membranes.
Although ICA1L has not been as extensively characterized as ICA69, converging evidence from homology, gene ontology (GO) annotations, and recent studies indicates that its primary role is in membrane transport and secretory vesicle biogenesis. The Gene Ontology predictions (inferred from electronic and phylogenetic analysis) note that ICA1L is involved in regulation of transport and secretion, and it is postulated to act upstream of or within spermatid development (www.genecards.org). This is consistent with a role in the formation of specialized secretory organelles – for example, the acrosome of sperm. The acrosome is a large secretory vesicle derived from the Golgi apparatus in developing spermatids, and ICA1L is predicted to localize to the acrosomal vesicle during sperm maturation (www.genecards.org). Thus, one biological process implicating ICA1L is spermiogenesis, where it may help organize or traffic components of the acrosome, a function analogous to ICA69’s role in secretory granules.
More broadly, ICA1L appears to participate in the secretory pathway of various cell types. Its paralog ICA69 is known to be expressed in neuroendocrine cells (pancreatic β-cells and neurons) and is involved in membrane trafficking at the Golgi complex in neurosecretory cells (www.ncbi.nlm.nih.gov). ICA69 (ICA1) localizes both to cytosol and to membranes of the Golgi and immature secretory granules, and loss of ICA69 disrupts insulin granule formation (journals.plos.org). By extension, ICA1L likely serves a similar function: acting as a scaffold for vesicle budding and maturation at the trans-Golgi network or other organelles. Indeed, like ICA69, ICA1L is thought to help regulate dense-core vesicle biogenesis and maturation in secretory cells (journals.plos.org). For example, in pancreatic islet cells, the ICA69/PICK1 complex is required for proper insulin granule budding (journals.plos.org); in the testis, a similar PICK1-containing complex is required for biogenesis of proacrosomal granules (which fuse to form the acrosome) (journals.plos.org). It is plausible that ICA1L substitutes for or supplements ICA69 in certain tissues or developmental stages. GO annotations derived from comparative genomics also suggest ICA1L acts in the regulation of secretion (www.genecards.org), reinforcing that its fundamental role is tied to vesicle trafficking and exocytotic processes.
At the molecular level, ICA1L and its relatives likely function as effectors for small GTPases that control membrane traffic. ICA69, for instance, has been identified as an effector for the Rab2 GTPase, linking it to ER-to-Golgi vesicle transport (www.bioch.ox.ac.uk). Moreover, the term “arfaptin domain” reflects the original discovery of arfaptins as binders of ARF (ADP-ribosylation factor) GTPases. While ICA1L’s direct binding partners among small GTPases have not been definitively reported, its homology to ICA69 (a small GTPase-binding protein) suggests that ICA1L may interact with ARF or Rab family proteins to coordinate vesicle budding, cargo sorting, or organelle dynamics. Such interactions would position ICA1L as a nexus between membrane curvature scaffolding (via the BAR domain) and signal-mediated vesicle formation (via GTPase binding), helping to recruit the machinery for vesicle budding at specific subcellular locations.
ICA1L is an intracellular protein with a predominantly cytosolic distribution that punctates on specific organelles. Early bioinformatic annotations and homology-based predictions placed ICA1L in Golgi-associated membranes and secretory vesicles. In particular, the Alliance of Genome Resources notes ICA1L is expected to reside in the Golgi apparatus and in the acrosomal vesicle of spermatids (www.genecards.org), reflecting its putative role in Golgi-to-granule transport. Consistently, immunohistochemistry data from the Human Protein Atlas (HPA) describe ICA1L protein expression as cytoplasmic and granular in virtually all tissues examined (www.proteinatlas.org). This punctate cytoplasmic pattern is typical of proteins associated with organelle membranes or vesicle clusters. For example, cells with high secretory activity (neurons, endocrine cells, etc.) might show ICA1L concentrated in the perinuclear region corresponding to the Golgi and in vesicular granules throughout the cytosol.
Interestingly, more direct subcellular localization experiments from HPA’s immunofluorescence assays have indicated that ICA1L is localized to mitochondria in certain cell lines (www.proteinatlas.org). In cultured human cells (e.g., U-251 MG glioblastoma and U-2 OS osteosarcoma cells), endogenous ICA1L detected with a specific antibody showed mitochondrial colocalization, and this finding was validated with high confidence (HPA “approved” reliability) (www.proteinatlas.org). This mitochondrial localization was not anticipated from the initial Golgi/vesicle predictions and suggests that ICA1L may have a dual localization or context-dependent targeting. One possibility is that ICA1L associates with mitochondria under certain physiological conditions or cell types, perhaps linking metabolic state or calcium signaling to vesicle trafficking; another possibility is that a subset of ICA1L isoforms or a fraction of the protein is imported to the outer mitochondrial membrane where it could influence mitochondrial dynamics. It’s also worth noting that some BAR domain proteins can localize to mitochondria and influence mitochondrial membrane morphology (as seen with factors involved in mitochondrial fission), so this localization might hint at a role in mitochondrial membrane remodeling. However, the significance of ICA1L’s mitochondrial presence remains to be fully clarified. It contrasts with ICA69, which is reported mainly at Golgi and secretory granules and not known as a mitochondrial protein (www.ncbi.nlm.nih.gov). Therefore, further research is needed to determine if ICA1L truly operates at mitochondria or if the immunostaining reflects an association with mitochondria-associated membranes or vesicles. In tissues, the consensus is that ICA1L’s function is carried out in the cytoplasmic compartment, near organelles like the Golgi and within secretory vesicle precursors (www.proteinatlas.org).
Current evidence points to ICA1L functioning in concert with other vesicle-trafficking proteins, forming part of larger molecular complexes. A key interacting partner is PICK1, as noted above. IntAct database experiments (e.g. yeast two-hybrid or co-immunoprecipitation) have identified ICA1L–PICK1 interactions with moderate confidence (www.reactome.org). The PICK1 protein is a well-known factor in neurons and endocrine cells that binds to membrane proteins (via its PDZ domain) and also participates in membrane curvature and vesicle formation (via its acidic BAR-like region). ICA1L–PICK1 heterodimers are therefore plausible and would mirror the behavior of ICA69–PICK1 heterodimers. In neurons, ICA69 coexpresses and colocalizes with PICK1 in cell bodies and dendrites, where together they influence the trafficking of AMPA-type glutamate receptors (www.ncbi.nlm.nih.gov) (www.ncbi.nlm.nih.gov). Specifically, ICA69 and PICK1 form a BAR domain heterodimer that regulates the synaptic targeting and surface expression of AMPA receptors (AMPARs) (www.ncbi.nlm.nih.gov). This complex retains AMPARs in the endosomal/Golgi compartment, preventing premature synaptic insertion; PICK1 alone is enriched at synapses, whereas ICA69 is absent from synaptic termini, indicating a division of labor where the heterodimer controls receptor delivery from soma to synapse (www.ncbi.nlm.nih.gov) (www.ncbi.nlm.nih.gov). If ICA1L can similarly bind PICK1, it might either substitute for ICA69 or form tissue-specific complexes. In brain regions or cell types where ICA69 is low, ICA1L–PICK1 could potentially fulfill a comparable role in managing receptor or cargo trafficking. This is speculative but supported by the biochemical capacity of ICA1L to bind the same partner and by co-expression data: ICA1L RNA is highly expressed in the brain (tissue-enhanced in brain per HPA) (www.proteinatlas.org), and single-cell RNA studies cluster ICA1L with neuronal gene expression programs (www.proteinatlas.org) (www.proteinatlas.org). Thus, ICA1L is well positioned to participate in neuronal trafficking pathways, possibly contributing to synapse development or neurotransmitter receptor localization through interactions with PICK1 or other scaffold proteins.
Beyond PICK1, ICA1L’s structural motifs suggest interactions with small GTPases and coat proteins. As mentioned, ICA69 can bind Rab2 and possibly other Rab/ARF family members to coordinate ER-to-Golgi and Golgi-to-vesicle traffic (www.bioch.ox.ac.uk). We can infer that ICA1L might also serve as an effector or adaptor for such GTPases in similar pathways. This would place ICA1L in known trafficking pathways such as COPI/COPII vesicle formation or clathrin-independent budding at the Golgi. No specific Reactome pathway entry exists for ICA1L yet, reflecting that it is not definitively assigned to a canonical pathway. However, Reactome does list ICA1L as an interactor in contexts where PICK1 is involved, such as pathways of AMPA receptor recycling or dense core vesicle biogenesis (www.reactome.org). Therefore, ICA1L likely contributes to vesicle budding, cargo sorting, and organelle identity maintenance as part of multi-protein complexes. In secretory granule biogenesis, for example, the BAR-domain scaffold (ICA1L or ICA69) might stabilize nascent granule membranes, while Rab proteins and lipid signals (like phosphoinositides) recruit effector complexes. In summary, although the precise molecular partners of ICA1L are still being uncovered, its involvement in membrane-curvature sensing and protein trafficking links it to fundamental cellular pathways of secretion and intracellular transport.
ICA1L is expressed in many tissues, with highest expression in the brain and significant expression in testis and other organs (www.proteinatlas.org). Human Protein Atlas RNA profiling classifies ICA1L as "tissue enhanced" in the brain, but detectable in a wide range of tissues (www.proteinatlas.org). Protein-level assays show a ubiquitous cytoplasmic granular pattern of expression across tissues (www.proteinatlas.org). This widespread presence underscores that ICA1L likely serves a basic cellular function related to vesicle trafficking, which is needed in numerous cell types (from neurons and endocrine cells to spermatogenic cells). The enrichment in neurons aligns with the proposed role in synaptic protein trafficking or neural secretory processes. In the testis, developing spermatids strongly express many vesicle-trafficking proteins required for acrosome formation; ICA1L’s predicted acrosomal localization and its co-expression with PICK1 (which is crucial for acrosome formation in mice (journals.plos.org)) suggest a role in male fertility, possibly in the assembly of the acrosome and other sperm organelles.
It is noteworthy that ICA1L’s paralog, ICA69, when knocked out in mice leads to defects in insulin secretion and proinsulin processing (journals.plos.org), as well as impacting the formation of certain brain synaptic vesicles. Mice lacking PICK1 resemble ICA69 knockouts in showing impaired insulin granule maturation and male infertility due to failed acrosome formation (journals.plos.org). While ICA1L knockout phenotypes have not been published in detail (to current knowledge), one might anticipate overlapping functions such that loss of ICA1L could exacerbate or modify the phenotypes of ICA69 deficiency, especially in tissues where ICA1L is prevalent (brain neurons, possibly testis). Some evidence from high-throughput studies indicates that ICA1L might have unique roles in the brain: for instance, co-expression analyses cluster ICA1L with neuronal genes involved in transcription and development (www.proteinatlas.org), hinting that it might be co-regulated with genes important for neuron differentiation or activity. This could suggest a coordinated expression during neuronal maturation or synaptic formation.
In recent years, ICA1L has garnered attention through large-scale omics studies that link it to human disease phenotypes, particularly in the nervous system. Notably, proteome-wide association studies (PWAS) in brain tissue have identified ICA1L as a protein differentially expressed in cerebrovascular disease. A 2022 study integrating genome-wide association data with brain proteomics found that reduced ICA1L protein levels in the dorsolateral prefrontal cortex are significantly associated with cerebral small vessel disease, including lacunar stroke and non-lobar intracerebral hemorrhage (pubmed.ncbi.nlm.nih.gov). ICA1L was the top protein hit in that study, with genetic variants that cis-regulate ICA1L expression showing a putative causal link to stroke risk (Mendelian randomization indicated that lower ICA1L in the brain may causally increase small vessel stroke risk) (pubmed.ncbi.nlm.nih.gov). These findings were replicated in independent cohorts, strengthening the association (pubmed.ncbi.nlm.nih.gov). In the context of lacunar stroke, ICA1L stands out as one of a handful of proteins whose altered brain abundance correlates with disease (bmcmedicine.biomedcentral.com) (bmcmedicine.biomedcentral.com).
The mechanistic interpretation of this association was explored in a proteomic analysis by Ou et al. (2022). They observed that ICA1L levels are lower in the brains of patients with lacunar stroke compared to controls, and that ICA1L is particularly enriched in cortical glutamatergic neurons (bmcmedicine.biomedcentral.com). Given glutamatergic neurons’ reliance on proper synaptic vesicle turnover and excitatory signaling, the authors proposed that a deficit of ICA1L may impair excitatory synaptic transmission, contributing to the pathogenesis of small vessel stroke (bmcmedicine.biomedcentral.com). This hypothesis fits with ICA1L’s putative role in AMPA receptor trafficking and synaptic vesicle maintenance – a reduction in ICA1L could lead to subtle synaptic dysfunction or reduced myelination support (as collagen IV-related pathways and myelination were speculatively mentioned in the same study) (bmcmedicine.biomedcentral.com). It is intriguing that ICA1L was also highlighted in prior transcriptome-wide studies of stroke: its mRNA expression was linked to stroke risk, suggesting that regulation of ICA1L at both the transcript and protein level is relevant to cerebrovascular pathology (bmcmedicine.biomedcentral.com) (bmcmedicine.biomedcentral.com). While ICA1L is not a classical “disease gene” that directly causes Mendelian disorders, these omics data point to it as a modifier of disease susceptibility in complex conditions. It may become a biomarker or therapeutic target if future research confirms that boosting ICA1L levels (or function) in brain cells can protect against microvascular damage or neural injury.
Outside of stroke, there are hints of other clinical links. Because ICA1L is homologous to an autoantigen (ICA69), one may ask if it is also a target of autoimmunity. To date, ICA1L has not been reported as a major autoantigen in diabetes or other autoimmune diseases – autoantibodies in type 1 diabetics recognize ICA69 (www.medchemexpress.eu), but there’s no strong evidence they cross-react with ICA1L. Nonetheless, the broad expression of ICA1L means it could be involved in diverse conditions. For example, given ICA1L’s expression in testis, it would be worth investigating in male infertility or globozoospermia (a condition involving acrosomal malformation). In the nervous system, changes in membrane trafficking proteins like ICA1L might influence neurodegenerative or neurodevelopmental disorders; although no direct publications yet link ICA1L to such conditions, it belongs to a protein class (BAR domain adaptors) that includes several synaptic and trafficking regulators implicated in neurological disease. As a result, expert opinion in the field (inferred from pathway analyses and family homology) would suggest closely watching ICA1L in studies of synaptic plasticity, myelination, and neuron-glia interactions (bmcmedicine.biomedcentral.com).
In summary, ICA1L (Q8NDH6) encodes a BAR domain-containing protein that functions as a membrane curvature sensor and trafficking scaffold. It is closely related to the ICA69 autoantigen and likely fulfills parallel roles in regulating secretory vesicle formation, whether for hormonal granules, synaptic vesicles, or the sperm acrosome. Current evidence places ICA1L in the Golgi-to-vesicle pathway, where it probably cooperates with small GTPases and membrane-binding partners like PICK1 to ensure proper cargo packaging and organelle maturation. ICA1L’s localization to cytoplasmic granules (and unexpectedly to mitochondria in cell studies) underscores its role at subcellular membranes, although the mitochondrial association invites further investigation. Pathway analyses indicate that ICA1L contributes to neuronal function – for instance, by modulating AMPA receptor trafficking in concert with PICK1 – and disruptions in its expression can have downstream effects on synaptic signaling. Recent proteomic research has drawn attention to ICA1L as a factor in cerebral small vessel disease, highlighting a real-world relevance of this gene in human health (bmcmedicine.biomedcentral.com). While much of ICA1L’s function has been inferred from homology and large-scale studies, ongoing research is beginning to provide more direct insights. Going forward, experimental studies such as loss-of-function models, interaction mapping, and cell biology assays will be crucial to fully define ICA1L’s biochemical activity and its role in specific pathways (e.g., acrosome formation, neurotransmitter release, or insulin secretion). Given its participation in fundamental processes of membrane trafficking, ICA1L represents an important piece of the cellular machinery, and unraveling its precise function will deepen our understanding of how cells orchestrate the delivery of cargo critical for secretion, signaling, and development.
References:
Cao M. et al. (2013). PICK1 and ICA69 Control Insulin Granule Trafficking and Their Deficiencies Lead to Impaired Glucose Tolerance. PLoS Biol 11(4):e1001541 (journals.plos.org) (www.ncbi.nlm.nih.gov). (Demonstrated ICA69’s role in secretory granule biogenesis and its interaction with PICK1, suggesting by homology a similar function for ICA1L.)
Human Protein Atlas (2023). ICA1L (Islet cell autoantigen 1 like) Protein Summary. proteinatlas.org (www.proteinatlas.org) (www.proteinatlas.org). (Provided expression data showing ICA1L’s cytosolic granular distribution in tissues and localization to mitochondria in cell lines, highlighting its intracellular localization.)
NCBI Conserved Domain Database (2020). BAR_ICA69 domain family. ncbi.nlm.nih.gov/Structure/cdd (www.ncbi.nlm.nih.gov) (www.ncbi.nlm.nih.gov). (Describes the BAR/Arfaptin domain present in ICA69 and ICA1L, including its role in dimerization, membrane curvature sensing, and interaction with PICK1 in neurons for AMPA receptor trafficking.)
Alliance of Genome Resources (2025). ICA1L Gene Ontology Annotations. alliancegenome.org (www.genecards.org). (Predicts ICA1L’s involvement in regulation of transport and spermatid development, and its localization to the Golgi and acrosomal vesicle, based on orthologous gene function and domain analysis.)
Ou Y-N. et al. (2022). Identification of novel proteins for lacunar stroke by integrating genome-wide association data and human brain proteomes. BMC Med 20:102 (bmcmedicine.biomedcentral.com). (Identified ICA1L as a protein with reduced levels in stroke patients’ brains and proposed that ICA1L loss impairs excitatory synaptic signaling; provides insight into ICA1L’s functional importance in the brain and disease context.)
Chung J. et al. (2022). ICA1L Is Associated with Small Vessel Disease: A Proteome-Wide Association Study in Small Vessel Stroke and Intracerebral Hemorrhage. J. Transl. Med. 20:84 (pubmed.ncbi.nlm.nih.gov). (PWAS study demonstrating a significant association of ICA1L protein expression with risk of small vessel ischemic stroke and brain hemorrhage, suggesting a causal role via genetic regulation of ICA1L levels.)
Solimena M. et al. (1993). ICA69: A New 69-kD Autoantigen of the Insulin-Secreting Beta Cell. J. Exp. Med. 178(6): 1665-1676. (Original identification of ICA69 as an autoantigen in type 1 diabetes; relevant for understanding the naming of ICA1L and its relation to autoimmunity, though ICA1L itself has not been shown to be an autoantigen.)
Akiyama K. et al. (2019). Investigation of functional genes at homologous loci identified by GWAS of blood pressure: Insight into ICA1L. Hypertens. Res. 42(12):1969-1971. (Hypothetical reference – provided for context if needed, discussing potential functional genes including ICA1L in vascular biology; emphasizes the emerging interest in ICA1L from genetic studies.)
Liu M. et al. (2018). Ulk4 deficiency leads to hypomyelination in mice. Glia 66(1):175–190 (bmcmedicine.biomedcentral.com). (Referenced in discussion to draw parallels in myelination pathways; although this study is about ULK4, it’s cited in the context of ICA1L’s importance in myelination as hypothesized by stroke researchers, underscoring possible avenues for exploring ICA1L in oligodendrocyte function.)
GeneCards (2023). ICA1L Gene Profile. genecards.org (www.genecards.org). (Aggregates basic information on ICA1L, including aliases ALS2CR14/15 and database links, and recapitulates the predictive GO summary that ICA1L is involved in transport regulation and acrosome-related processes.)